Year Two of This Alport Syndrome Trial Concludes with Encouraging Findings
source: pixabay.com

Year Two of This Alport Syndrome Trial Concludes with Encouraging Findings

According to a story from GlobeNewswire, the biopharmaceutical company Reata Pharmaceuticals, Inc., recently announced that year two of its phase 3 clinical trial has been completed. This trial is testing…

Continue Reading Year Two of This Alport Syndrome Trial Concludes with Encouraging Findings

Could Stopping Using the Word “Rare” Increase the Rate of Diagnosis for Rare Disease Patients?

The Word "Rare" Unfortunately, many experts in rare disease believe the phrase "rare disease" may be harming the very population it describes. The Director of the National Center for Advancing…

Continue Reading Could Stopping Using the Word “Rare” Increase the Rate of Diagnosis for Rare Disease Patients?

Results From Studies of an Experimental Drug for Chronic Kidney Disease Have Been Announced

Results from two studies looking at the effects of an experimental drug (bardoxolone) on kidney function in patients with chronic kidney disease (CKD) have been released. One of the studies…

Continue Reading Results From Studies of an Experimental Drug for Chronic Kidney Disease Have Been Announced